The Fed turned up the heat around a possible December rate hike, just as the government is about to release a report expected to show sluggish GDP growth.
Jim Cramer says to wait for this group to come in before pouncing on this stock when he gave his take on caller favorite stocks.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
As the third-quarter earnings season gets underway, here are some lesser-known plays from some of today's top money managers.
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
Fears of tepid global world took center stage this week once again, sending equity benchmarks across the board in the red this week.
CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.
Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?
Singapore’s $196 billion sovereign wealth fund Temasek is sticking with its China bets, looking past recent volatility to gradually increase its exposure.
Over 10 years, the month of July has averaged stock market gains across the major U.S. indexes.
CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
TIAA-CREF portfolio manager Saira Malik sees opportunity with a likely market correction before a Fed rate hike. Here are her picks.
This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.
A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.
The next takeout target in biotech? Here are three eligible candidates
Evercore ISI’s Mark Schoenebaum couldn't believe the Alexion and Synageva deal.
Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.
After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.
Some of the names on the move ahead of the open.